Parx Materials N.V. has received a capital injection of €1m for expansion and scale-up. This investment enables Parx Materials (as of January 29 the new name of the company formerly named Parx Plastics) to expand its team and make the required investments for the scaling up of the production of Saniconcentrate.
via Shutterstock
Parx Materials receives €1m investment
Belgian company Lausha N.V. is making the capital injection and obtaining an equity stake of 12.5%.
Co-founder and CEO Michaël van der Jagt said: "We are pleased to welcome this investor on-board and we are happy to see the continued support in our efforts to bring this exciting technology into the market. With this investment we are able to take the next steps in expansion and scaling, allowing us to move faster and bringing some new developments closer."
With the recent developments, Parx is making exciting steps in the development and commercialising of its unique antimicrobial and antibiofilm technology. On 20 December 2019, the company was able to announce a signed co-operation agreement with PepsiCo in Purchase, New York, and it is seeing excellent adoption of its technology in the supermarket channel in the UK and elsewhere.
Parx specialises in the development and manufacturing of materials with sustainable antimicrobial and antibiofilm properties. The company's technology does not contain harmful or toxic chemicals, biocides, heavy metals or nanoparticles. It can be used with any type of plastic and for any type of application. It is fully biocompatible and does not diffuse out of the material. Also, it prevents bacteria and micro-organisms accumulating on the surface of a product with an efficacy of 99.9% and higher within 24 hours.